JSPR Stock Overview
A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Jasper Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.74 |
| 52 Week High | US$26.84 |
| 52 Week Low | US$3.13 |
| Beta | 2.76 |
| 1 Month Change | 13.94% |
| 3 Month Change | -11.90% |
| 1 Year Change | -77.17% |
| 3 Year Change | -84.04% |
| 5 Year Change | -95.12% |
| Change since IPO | -95.17% |
Recent News & Updates
Recent updates
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?
Jan 04
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma
Nov 18We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate
Aug 30We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully
Jan 23Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth
Jul 31We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate
Feb 02Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely
Oct 14Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02
Aug 12Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?
Jun 19Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning
Nov 28We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth
Nov 23Shareholder Returns
| JSPR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.4% | -2.6% | 3.9% |
| 1Y | -77.2% | -12.1% | 11.6% |
Return vs Industry: JSPR underperformed the US Biotechs industry which returned -15.3% over the past year.
Return vs Market: JSPR underperformed the US Market which returned 8% over the past year.
Price Volatility
| JSPR volatility | |
|---|---|
| JSPR Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: JSPR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: JSPR's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 64 | Ron Martell | jaspertx.com |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.
Jasper Therapeutics, Inc. Fundamentals Summary
| JSPR fundamental statistics | |
|---|---|
| Market cap | US$67.90m |
| Earnings (TTM) | -US$71.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs JSPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JSPR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$71.27m |
| Earnings | -US$71.27m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did JSPR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 05:27 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jasper Therapeutics, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Etzer Darout | BMO Capital Markets Equity Research |
| Justin Zelin | BTIG |